These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33437513)

  • 1. Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients.
    Schlick K; Hohla F; Hamacher F; Hackl H; Hufnagl C; Markus S; Magnes T; Gampenrieder SP; Melchardt T; Stättner S; Hauser-Kronberger C; Greil R; Rinnerthaler G
    Future Sci OA; 2020 Nov; 7(2):FSO644. PubMed ID: 33437513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.
    Meijer LL; Garajová I; Caparello C; Le Large TYS; Frampton AE; Vasile E; Funel N; Kazemier G; Giovannetti E
    Ann Surg; 2020 Jun; 271(6):1137-1147. PubMed ID: 30394883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer.
    Ohuchida K; Mizumoto K; Kayashima T; Fujita H; Moriyama T; Ohtsuka T; Ueda J; Nagai E; Hashizume M; Tanaka M
    Ann Surg Oncol; 2011 Aug; 18(8):2381-7. PubMed ID: 21347785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study.
    van der Sijde F; Homs MYV; van Bekkum ML; van den Bosch TPP; Bosscha K; Besselink MG; Bonsing BA; de Groot JWB; Karsten TM; Groot Koerkamp B; Haberkorn BCM; Luelmo SAC; Mekenkamp LJM; Mustafa DAM; Wilmink JW; van Eijck CHJ; Vietsch EE; On Behalf Of The Dutch Pancreatic Cancer Group
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers.
    Calatayud D; Dehlendorff C; Boisen MK; Hasselby JP; Schultz NA; Werner J; Immervoll H; Molven A; Hansen CP; Johansen JS
    Biomark Res; 2017; 5():8. PubMed ID: 28239461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.
    Shen Y; Pan Y; Xu L; Chen L; Liu L; Chen H; Chen Z; Meng Z
    Tumour Biol; 2015 Jun; 36(6):4525-34. PubMed ID: 25722110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Serum microRNA Let-7c and Let-7d as Predictive Biomarkers for Metastatic Pancreatic Cancer.
    Demiray AG; Demiray A; Yaren A; Yapar Taşköylü B; Gököz Doğu G; Değirmencioğlu S; Çakıroğlu U; Özhan N; Karan C; Çakan Demirel B; Doğan T; Özdemir M
    Turk J Gastroenterol; 2022 Aug; 33(8):696-703. PubMed ID: 35943151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-296-5p Promotes Cell Invasion and Drug Resistance by Targeting Bcl2-Related Ovarian Killer, Leading to a Poor Prognosis in Pancreatic Cancer.
    Okazaki J; Tanahashi T; Sato Y; Miyoshi J; Nakagawa T; Kimura T; Miyamoto H; Fujino Y; Nakamura F; Takehara M; Ma B; Bando M; Kitamura S; Okamoto K; Muguruma N; Sogabe M; Takayama T
    Digestion; 2020; 101(6):794-806. PubMed ID: 31563901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
    Lu H; Lu S; Yang D; Zhang L; Ye J; Li M; Hu W
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30777929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.
    Melisi D; Garcia-Carbonero R; Macarulla T; Pezet D; Deplanque G; Fuchs M; Trojan J; Kozloff M; Simionato F; Cleverly A; Smith C; Wang S; Man M; Driscoll KE; Estrem ST; Lahn MMF; Benhadji KA; Tabernero J
    Cancer Chemother Pharmacol; 2019 May; 83(5):975-991. PubMed ID: 30887178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
    Raphael MJ; Raskin W; Habbous S; Tai X; Beca J; Dai WF; Arias J; Forbes L; Gavura S; Biagi JJ; Earle CC; Chan KKW
    JAMA Netw Open; 2021 Nov; 4(11):e2133388. PubMed ID: 34779846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma.
    Zhou L; Jia S; Ding G; Zhang M; Yu W; Wu Z; Cao L
    J Cancer; 2019; 10(21):5031-5040. PubMed ID: 31602254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
    Queck A; Elango S; Koch C; Walter D; Schmidt J; Trebicka J; Trojan J; Pession U; Finkelmeier F; Waidmann O
    Oncol Res Treat; 2022; 45(3):79-87. PubMed ID: 34875671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-7 as a Potential Biomarker for Prognosis in Pancreatic Cancer.
    Ye ZQ; Zou CL; Chen HB; Jiang MJ; Mei Z; Gu DN
    Dis Markers; 2020; 2020():2782101. PubMed ID: 32566037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.
    Pan Y; Li K; Tao X; Zhao Y; Chen Q; Li N; Liu J; Go VLW; Guo J; Gao G; Xiao GG
    Pancreas; 2021 Oct; 50(9):1260-1266. PubMed ID: 34860809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [DNA microarrays-based microRNA expression profiles derived from formalin-fixed paraffin-embedded tissue blocks of squammous cell carcinoma of larynx].
    Li L; Zhang ZM; Liu Y; Wei MH; Xue LY; Zou SM; Di XB; Han NJ; Zhang KT; Xu ZG; Gao YN
    Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):391-5. PubMed ID: 21055156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes.
    Zhou C; Yi C; Yi Y; Qin W; Yan Y; Dong X; Zhang X; Huang Y; Zhang R; Wei J; Ali DW; Michalak M; Chen XZ; Tang J
    Mol Cancer; 2020 Jul; 19(1):118. PubMed ID: 32727463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.
    Muranaka T; Kuwatani M; Komatsu Y; Sawada K; Nakatsumi H; Kawamoto Y; Yuki S; Kubota Y; Kubo K; Kawahata S; Kawakubo K; Kawakami H; Sakamoto N
    J Gastrointest Oncol; 2017 Jun; 8(3):566-571. PubMed ID: 28736643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer.
    Hiramoto H; Muramatsu T; Ichikawa D; Tanimoto K; Yasukawa S; Otsuji E; Inazawa J
    Sci Rep; 2017 Jun; 7(1):4002. PubMed ID: 28638102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study.
    Kim JH; Lee SC; Oh SY; Song SY; Lee N; Nam EM; Lee S; Hwang IG; Lee HR; Lee KT; Bae SB; Kim HJ; Jang JS; Lim DH; Lee HW; Kang SY; Kang JH
    Cancer Commun (Lond); 2018 Jun; 38(1):32. PubMed ID: 29866170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.